<DOC>
	<DOCNO>NCT02813200</DOCNO>
	<brief_summary>Chronic Obstructive Pulmonary Disease ( COPD ) fourth lead cause death world increase prevalence mortality predict . Currently , main long-term treatment long-acting beta-2 agonist , indacaterol , salmeterol anticholinergic drug , tiotropium glycopyrronium , use alone combination : - long-acting beta-2 agonist corticosteroid ( e.g . salmeterol/fluticasone ) , - long-acting beta-2 agonist anticholinergic ( e.g . indacatetrol/glycopyrronium ) . These drug deliver lung use different inhaler device Breezhaler ® , Handihaler® Diskus® .</brief_summary>
	<brief_title>Description Ability Learn How Handle Inhaler Devices COPD</brief_title>
	<detailed_description>The correct use inhaler device inclusion criterion COPD clinical trial . In real life , patient may make many error use inhaler device , may alter positive effect observe clinical trial . The main objective study describe handle inhaler device ( indacaterol-glycopyrronium Breezhaler® , tiotropium Respimat® salmeterol-fluticasone Diskus® ) patient COPD . All participant receive three treatment ( Seretide® Diskus® 500/550 μg , Ultibro® Breezhaler® 110/50 μg Spiriva® Respimat® 2,5 μg ) . Each treatment give daily one week , follow 7-day washout period . On day 1 treatment period , patient clinical examination , lung function test ( FEV1 ) 2 video recording : - Video record # 1 : inhalation ( one puff ) without instruction use , - Video record # 2 : inhalation ( one puff ) read patient information leaflet . At end visit , patient watch standardize video demonstrate correct inhaler technique . On day 7 treatment period , patient clinical examination , lung function test ( FEV1 ) 1 video record inhaler device use ( one puff ) . 30 day last visit , patient phone contact collect adverse event .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Male female age 40 year , Written inform consent , Diagnosis COPD accord international guideline ( GOLD 2012 ) , Social security health insurance , Women childbearing potential effective contraception accord Haute Autorité de Santé ( HAS ) recommendation . Previous treatment Breezhaler® , Diskus® Respimat® similar device , QT ≥ 450 m , Contraindications tiotropium : hypersensitivity tiotropium , Contraindications indacatérol : hypersensitivity indacatérol , Contraindications salmeterol : hypersensitivity salmeterol , Contraindications fluticasone : hypersensitivity fluticasone , Contraindications glycopyrronium : hypersensitivity glycopyrronium , COPD exacerbation within 6 week inclusion , Chronic psychiatric disease , Medical condition may affect handle inhaler device , Subject deprive his/her liberty , Protected adult , Subject exclusion period relate another protocol , Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>COPD , inhaler device , handle</keyword>
</DOC>